Canaccord Genuity Maintains a 'Hold' on Becton Dickinson (BDX); Introduces Next-gen Lateral Flow Flu Test
Tweet
Share
E-mailGet Alerts BDX Hot Sheet
Price: $187.62 --0%
Rating Summary:
13 Buy, 12 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 5 | New: 12
Rating Summary:
13 Buy, 12 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 5 | New: 12
Join SI Premium – FREE
Canaccord Genuity maintains a 'Hold' on Becton Dickinson (NYSE: BDX) price target of $78.00.
Canaccord analyst, Jeffrey Frelick, said, "BDX announced today that it received both FDA 510(k) clearance and CLIA waiver for its next-gen lateral flow rapid flu test. This is the first CLIA-waived rapid flu test system that produces digital, objective results. Although positive for BDX, we maintain our rating as we wait for more meaningful products to launch in 2012."
For an analyst ratings summary and ratings history on Becton Dickinson click here. For more ratings news on Becton Dickinson click here.
Shares of Becton Dickinson closed at $70.66 yesterday.
Canaccord analyst, Jeffrey Frelick, said, "BDX announced today that it received both FDA 510(k) clearance and CLIA waiver for its next-gen lateral flow rapid flu test. This is the first CLIA-waived rapid flu test system that produces digital, objective results. Although positive for BDX, we maintain our rating as we wait for more meaningful products to launch in 2012."
For an analyst ratings summary and ratings history on Becton Dickinson click here. For more ratings news on Becton Dickinson click here.
Shares of Becton Dickinson closed at $70.66 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Limbach Holdings (LMB) to Underweight
- Deutsche Bank Downgrades Straumann Holding AG (STMN:SW) (SAUHF) to Hold
- UBS Downgrades Vicinity Centers (VCX:AU) (CNRAF) to Neutral
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
